Ketogenic diet in cancer therapy
Open accessThe DOI matches its Crossref record.
Abstract
The Ketogenic Diet (KD), a high-fat/low-carbohydrate/ adequate-protein diet, has recently been proposed as an adjuvant therapy in cancer treatment [1]. KDs target the Warburg effect, a biochemical phenomenon in which cancer cells predominantly utilize glycolysis instead of oxidative phosphorylation to produce ATP. Furthermore, some cancers lack the ability to metabolize ketone bodies, due to mitochondrial dysfunction and down-regulation of enzymes necessary for ketone utilization [2]. Thus, the rationale in providing a fatrich, low-carbohydrate diet in cancer therapy is to reduce circulating glucose levels and induce ketosis such that cancer cells are starved of energy while normal cells adapt their metabolism to use ketone bodies and survive. Furthermore, by reducing blood glucose also levels of insulin and insulin-like growth factor, which are important drivers of cancer cell proliferation, drop. Numerous preclinical studies have provided evidence for an anti-tumor effect of KDs [1] (Figure 1). For example, our laboratory intensively studied the antitumor effect of KDs in combination with or without low-dose chemotherapy on neuroblastoma. We found that the growth of neuroblastoma xenografts was significantly reduced by a KD consisting of a 2:1 ratio of fat to carbohydrate + protein when combined with caloric restriction [2]. However, caloric restriction, despite its anti-tumor effect and potential to sensitize cancer cells to chemotherapy, would be contraindicated in a range of cancer patients, particularly those with cachexia. Thus, we further focused on optimizing the KD composition to address this issue. We found that an ad libitum KD (8:1) with a fat content of 25% mediumchain triglycerides and 75% long-chain triglycerides produced a stronger anti-tumor effect compared to a KD (8:1) with all long-chain triglycerides, and was as efficacious against neuroblastoma as the abovedescribed KD (2:1) combined with caloric restriction [3]. These results stress the importance of an optimized KD composition to suppress tumor growth and to sensitize tumors to chemotherapy without requiring caloric restriction. In addition to neuroblastoma, various researchers have investigated the efficacy of KDs as an adjuvant therapy for other types of cancer. The strongest evidence (> 3 studies) for a tumor-suppressing effect has been reported Editorial
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ketogenic diet in the treatment of cancer – Where do we stand?
Weber, D. D., Aminzadeh-Gohari, S., Tulipan, J., Catalano, L., Feichtinger, R. G., & Kofler, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.06.026 · Cited by 464
Self-citationTumor glycolysis, an essential sweet tooth of tumor cells
Paul, S., Ghosh, S., & Kumar, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.007 · Cited by 449
Dietary modifications for enhanced cancer therapy
Kanarek, N., Petrova, B., & Sabatini, D. M. (2020) · Nature · doi:10.1038/s41586-020-2124-0 · Cited by 411
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Metabolic communication in the tumour–immune microenvironment
Kao, K.-C., Vilbois, S., Tsai, C.-H., & Ho, P.-C. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01002-x · Cited by 349
Metabolic interventions in the immune response to cancer
O’Sullivan, D., Sanin, D. E., Pearce, E. J., & Pearce, E. L. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0140-9 · Cited by 312
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
Dietary patterns and cancer risk
Steck, S. E., & Murphy, E. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0227-4 · Cited by 292
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Xiang, Y., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 287
Yang, Y.-F., Mattamel, P. B., Joseph, T., Huang, J., Chen, Q., Akinwunmi, B. O., Zhang, C. J. P., & Ming, W.-K. (2021) · Nutrients · doi:10.3390/nu13051388 · Cited by 57
“This will also cause a reduction in insulin and insulin-like growth factors, which are known essential factors for the proliferation of cancer cells [9].”
BackgroundKetogenic diet and multiple health outcomes: an umbrella review of meta-analysis
Chen, S., Su, X., Feng, Y., Li, R., Liao, M., Fan, L., Liu, J., Chen, S., Zhang, S., Cai, J., et al. (2023) · Nutrients · doi:10.3390/nu15194161 · Cited by 41
Metadata
- Authors
- Weber, D. D., Aminazdeh-Gohari, S., & Kofler, B.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2018-02-11
- Volume
- 10
- Issue
- 2
- Pages
- 164-165
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W2791021289
- Cited by
- 156
- References
- 0
- FWCI
- 11.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.